The journal Cell is celebrating 50 years of metabolism research with a special Focus on Metabolism, illustrating its importance in so many processes and diseases.
Drug Approval News: The FDA has approved JNJ’s Rybrevant® (Amivantamab-vmjw plus Lazertinib) as a first line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. Lazertinib
August 1st is World RNA Day and Focus Biomolecules is celebrating! Check out our broad portfolio of small molecule research tools for studying RNA. Don’t see
Journal Club: An excellent review of the TRPV1 channel was recently published in Cell Calcium, covering its structure, activation, and modulation, as well as its role
Focus on Natural Products: Celebrating the birthday of Satoshi Omura (July 12). Omura is well known for his work on the isolation and structure identification of
Drug Approval News: Johnson & Johnson (J&J) has received approvals from both the European Commission (EC) and US Food and Drug Administration (FDA) for its tuberculosis
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.
